A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor
- Author:
You Cheol HWANG
1
;
Jae Hyeon KIM
;
Byung Wan LEE
;
Woo Je LEE
Author Information
- Publication Type:Multicenter Study
- Keywords: Diabetes mellitus, type 2; Glycosuria; Ipragliflozin; Sodium-glucose transporter 2
- MeSH: Blood Pressure; Body Weight; Creatinine; Diabetes Mellitus, Type 2; Glucose; Glycosuria; Hemoglobin A, Glycosylated; Prospective Studies; Sodium; Sodium-Glucose Transporter 2
- From:Diabetes & Metabolism Journal 2019;43(6):898-905
- CountryRepublic of Korea
- Language:English
- Abstract: We aimed to identify the clinical variables associated with a better glucose-lowering response to the sodium glucose cotransporter 2 inhibitor ipragliflozin in people with type 2 diabetes mellitus (T2DM). We especially focused on urinary glucose excretion (UGE). This was a single-arm multicenter prospective study. A total of 92 people with T2DM aged 20 to 70 years with glycosylated hemoglobin (HbA1c) levels ≥7.0% and ≤9.5% were enrolled. Ipragliflozin (50 mg) was added to the background therapy for these people for 12 weeks. After 3 months treatment with ipragliflozin, the mean HbA1c levels were decreased from 7.6% to 6.9% and 62.0% of the people reached the HbA1c target of less than 7.0% (P<0.001). In addition, body weight, blood pressure, and lipid parameters were improved after ipragliflozin treatment (all P<0.001). The baseline HbA1c (r=0.66, P<0.001) and morning spot urine glucose to creatinine ratio (r=−0.30, P=0.001) were independently associated with the HbA1c reduction. Ipragliflozin treatment for 12 weeks improves glycemic control and other metabolic parameters. A higher HbA1c and lower UGE at baseline predicts a better glucose-lowering efficacy of ipragliflozin.
